AI Article Synopsis
- - A safety analysis was conducted on dacomitinib, a drug used for patients with advanced non-small-cell lung cancer, focusing on the incidence of adverse drug reactions (ADRs) in 255 mutation-positive patients.
- - An overwhelming 98% of patients experienced ADRs, with diarrhea, rash, stomatitis, nail disorder, and dry skin being the most common; dose interruptions and reductions occurred in 47% and 52% of patients, respectively.
- - Overall, dacomitinib was found to be generally tolerable, with serious ADRs reduced after dose adjustments; most ADRs were manageable and consistent with known effects of EGFR tyrosine kinase inhibitors.
Article Abstract
This pooled safety analysis was conducted to analyze incidence and management of key dacomitinib-associated adverse drug reactions (ADRs). Patients with mutation-positive advanced non-small-cell lung cancer who received first-line dacomitinib at the 45 mg/day recommended starting dose were included. ADRs were identified based on reasonable association with EGFR tyrosine kinase inhibitors. Overall, 251/255 patients (98%) experienced ADRs. The most common were diarrhea, rash, stomatitis, nail disorder and dry skin. Dose interruptions and dose reductions were reported in 47 and 52% of patients, respectively. Fewer grade 3 key ADRs were observed following dose reductions. Dacomitinib was generally tolerable. Most reported ADRs were known to be associated with EGFR tyrosine kinase inhibitors and were managed with standard medical management and dose modifications.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2217/fon-2018-0944 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
[More Personalized Treatment using Diversified Molecular Targeted Therapy Strategies for EGFR Mutation-Positive Non-Small-Cell Lung Cancer-Sequential Treatment Comprising First- and Second-Line Therapy with EGFR-TKIs and Treatment Options in Combination with Anti-Angiogenic Agents].
Gan To Kagaku Ryoho
October 2024
Division of Medical Oncology, Dept. of Internal Medicine, Teikyo University School of Medicine.
Article Synopsis
- EGFR-TKIs are crucial for treating advanced non-small-cell lung cancer with EGFR gene mutations, with five variants approved in Japan, including gefitinib, erlotinib, afatinib, dacomitinib, and osimertinib.
- Osimertinib is the only EGFR-TKI approved for second-line therapy in patients with the T790M mutation after initial treatment, making it essential to choose the right first-line therapy carefully.
- The article presents clinical data on EGFR-TKIs for first and second-line treatments, highlights the importance of patient and mutation subtype considerations, and shares experiences from transitioning between these therapies.
Optimal first-line treatment for EGFR-mutated NSCLC: a comparative analysis of osimertinib and second-generation EGFR-TKIs.
BMC Pulm Med
October 2024
Department of Internal Medicine, Division of Pulmonary and Critical Care, China Medical University Hospital, Taichung, Taiwan.
Article Synopsis
- Osimertinib is a third-generation EGFR TKI that is commonly used as a first-line treatment for advanced EGFR-mutated non-small cell lung cancer (NSCLC), but its effectiveness compared to second-generation TKIs (afatinib and dacomitinib) hasn't been thoroughly studied.
- The study enrolled 168 patients with stage IIIb-IV EGFR-mutated NSCLC, finding that median progression-free survival (PFS) was not significantly different between those treated with osimertinib and those on second-generation TKIs.
- Results indicated that while osimertinib showed longer PFS in patients with certain mutations, none of the differences were statistically significant, and the stage of NSCLC was the only strong predictor
Efficacy and safety of dacomitinib as first-line treatment for advanced non-small cell lung cancer patients with epidermal growth factor receptor 21L858R mutation: A multicenter, case-series study in China.
Chin J Cancer Res
August 2024
Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/CancerHospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Article Synopsis
- The study aimed to evaluate the effectiveness and safety of dacomitinib, a treatment for patients with a specific mutation (21L858R) of non-small cell lung cancer in China, by tracking a cohort of 155 patients over time.
- Key findings showed a high response rate (70.9%) and a disease control rate of 96.3%, with a median progression-free survival of 16.3 months, suggesting that dacomitinib is an effective first-line therapy.
- Adverse events were primarily manageable, with rash and diarrhea being the most common serious side effects, and factors like initial dosage did not significantly impact the patient's survival outcomes.
Clinical and structural insights into the rare but oncogenic HER2-activating missense mutations in non-small cell lung cancer: a retrospective ATLAS cohort study.
Discov Oncol
July 2024
Department of Respiratory Medical Oncology, Shandong First Medical University and Shandong Academy of Medical Sciences, Shandong Cancer Hospital and Institute, No.440 Jiyan Road, Jinan, 250117, Shandong, China.
Background: Unlike human epidermal growth factor receptor 2 (HER2) amplification or exon 20 insertions, missense mutations in the extracellular domain (ECD), transmembrane domain (TMD), and intracellular domain (ICD) of the HER2 protein have been implicated as oncogenic in non-small cell lung cancer (NSCLC). However, their molecular subtypes, structural disparities, and clinical responses to current medical treatments, particularly HER2-targeted tyrosine kinase inhibitors (TKIs), remain unclear in NSCLC and warrant investigation.
Methods: A real-world observational ATLAS study was conducted to gather and analyze therapeutic outcomes of chemotherapy or TKIs for heterogeneous HER2 missense mutations in NSCLC.
Dacomitinib overcomes acquired resistance to osimertinib in advanced NSCLC patients with EGFR L718Q mutation: A two-case report.
Medicine (Baltimore)
July 2024
Department of Thoracic Internal Medicine, Liaoning Cancer Hospital and Institute, Cancer Hospital of China Medical University, Shenyang, China.
Rationale: Acquired resistance still inevitably occurs in patients treated with third-generation TKI osimertinib. Although the EGFR L718Q mutation has been reported as a scarce mechanism of osimertinib resistance, advanced therapeutic strategies are still in development. In this report, we included 2 cases of patients who acquired EGFR L858R/L718Q mutation after osimertinib and were overcome by dacomitinib.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!